Genome-based mutational analysis by next generation sequencing in patients with malignant pleural and peritoneal mesothelioma

Anticancer Research

Volumn 36, Issue 5, 2016, Pages 2331-2338

  Ugurluer, Gamze ^a,b   Chang, Kenneth ^a   Gamez, Mauricio E ^c   Arnett, Andrea L ^a   Jayakrishnan, Ritujith ^a   Miller, Robert C ^a,d   Sio, Terence T ^c  

^a MAYO CLINIC   (United States)

^b ACIBADEM UNIVERSITY   (Turkey)

^c MAYO CLINIC   (United States)

^d MAYO CLINIC   (United States)

Author keywords

BAP1; CDKNA2A B; Malignant mesothelioma; Molecular targeting therapy; Next generation sequencing; NF2

Indexed keywords

PEMETREXED; PHOSPHATIDYLINOSITOL 3 KINASE; DNA; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL PRACTICE; FEMALE; FIRST-DEGREE RELATIVE; FOLLOW UP; HUMAN; LUNG METASTASIS; MALE; MULTIMODALITY CANCER THERAPY; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; OVERALL SURVIVAL; PERITONEUM MESOTHELIOMA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEREOTACTIC BODY RADIATION THERAPY; ASBESTOSIS; COMPLICATION; DNA MUTATIONAL ANALYSIS; DNA SEQUENCE; GENETICS; KAPLAN MEIER METHOD; LUNG TUMOR; LYMPHOMA; MESOTHELIOMA; MIDDLE AGED; MORTALITY; PERITONEUM TUMOR; PLEURA TUMOR; PROCEDURES; RADIATION INDUCED NEOPLASM; SECOND CANCER; TUMOR GENE;

ADULT; AGED; ASBESTOSIS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GENES, NEOPLASM; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; LYMPHOMA; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASMS, RADIATION-INDUCED; NEOPLASMS, SECOND PRIMARY; PERITONEAL NEOPLASMS; PLEURAL NEOPLASMS; SEQUENCE ANALYSIS, DNA;

EID: 84989929921     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Robinson BW and Lake RA: Advances in malignant mesothelioma. N Engl J Med 353: 1591-1603, 2005.
2. Faig J, Howard S, Levine EA, Casselman G, Hesdorffer M and Ohar JA: Changing pattern in malignant mesothelioma survival. Transl Oncol 8: 35-39, 2015.
3. Dogan AU, Baris YI, Dogan M, Emri S, Steele I, Elmishad AG and Carbone M: Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey. Cancer Res 66: 5063-5068, 2006.
4. De Luca A, Baldi A, Esposito V, Howard CM, Bagella L, Rizzo P, Caputi M, Pass HI, Giordano GG, Baldi F, Carbone M and Giordano A: The retinoblastoma gene family pRb/p105, p107, pRb2/p130 and simian virus-40 large T-antigen in human mesotheliomas. Nat Med 3: 913-916, 1997.
5. Tward JD, Wendland MM, Shrieve DC, Szabo A and Gaffney DK: The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer 107: 108-115, 2006.
6. Gulmez I, Kart L, Buyukoglan H, Er O, Balkanli S and Ozesmi M: Evaluation of malignant mesothelioma in central Anatolia: a study of 67 cases. Can Respir J 11: 287-290, 2004.
7. Price B and Ware A: Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005. Crit Rev Toxicol 39: 576-588, 2009.
8. Stahel RA, Weder W, Felley-Bosco E, Petrausch U, Curioni-Fontecedro A, Schmitt-Opitz I and Peters S: Searching for targets for the systemic therapy of mesothelioma. Ann Oncol 26: 1649-1660, 2015.
9. Tada Y, Suzuki T, Shimada H, Hiroshima K, Tatsumi K and Tagawa M: Molecular-Targeted Therapy for Malignant Mesothelioma. Pleura 2: 1-11, 2015.
10. Delgermaa V, Takahashi K, Park EK, Le GV, Hara T and Sorahan T: Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ 89: 716-724, 2011.
11. Shukuya T, Serizawa M, Watanabe M, Akamatsu H, Abe M, Imai H, Tokito T, Ono A, Taira T, Kenmotsu H, Naito T, Murakami H, Takahashi T, Endo M, Ohde Y, Nakajima T, Yamamoto N and Koh Y: Identification of actionable mutations in malignant pleural mesothelioma. Lung Cancer 86: 35-40, 2014.
12. Merritt N, Blewett CJ, Miller JD, Bennett WF, Young JE and Urschel JD: Survival after conservative (palliative) management of pleural malignant mesothelioma. J Surg Oncol 78: 171-174, 2001.
13. Milano MT and Zhang H. Malignant pleural mesothelioma: a population-based study of survival. J Thorac Oncol 5: 1841-1848, 2010.
14. Grosso F and Scagliotti GV: Systemic treatment of malignant pleural mesothelioma. Future Oncol 8: 293-305, 2012.
15. Remon J, Reguart N, Corral J and Lianes P: Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies. Cancer Treat Rev 41: 27-34, 2015.
16. Kindler HL: Systemic treatments for mesothelioma: standard and novel. Curr Treat Options Oncol 9: 171-179, 2008.
17. Ladanyi M, Zauderer MG, Krug LM, Ito T, McMillan R, Bott M and Giancotti F: New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment. Clin Cancer Res 18: 4485-4490, 2012.
18. de Assis LV, Locatelli J and Isoldi MC: The role of key genes and pathways involved in the tumorigenesis of Malignant Mesothelioma. Biochim Biophys Acta 1845: 232-247, 2014.
19. Thurneysen C, Opitz I, Kurtz S, Weder W, Stahel RA and Felley-Bosco E: Functional inactivation of NF2/merlin in human mesothelioma. Lung Cancer 64: 140-147, 2009.
20. Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, Creaney J, Lake RA, Zakowski MF, Reva B, Sander C, Delsite R, Powell S, Zhou Q, Shen R, Olshen A, Rusch V and Ladanyi M: The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 43: 668-672, 2011.
21. Vrijenhoek T, Kraaijeveld K, Elferink M, de Ligt J, Kranendonk E, Santen G, Nijman IJ, Butler D, Claes G, Costessi A, Dorlijn W, van Eyndhoven W, Halley DJ, van den Hout MC, van Hove S, Johansson LF, Jongbloed JD, Kamps R, Kockx CE, de Koning B, Kriek M, Lekanne Dit Deprez R, Lunstroo H, Mannens M, Mook OR, Nelen M, Ploem C, Rijnen M, Saris JJ, Sinke R, Sistermans E, van Slegtenhorst M, Sleutels F, van der Stoep N, van Tienhoven M, Vermaat M, Vogel M, Waisfisz Q, Marjan Weiss J, van den Wijngaard A, van Workum W, Ijntema H, van der Zwaag B, van IJcken WF, den Dunnen J, Veltman JA, Hennekam R and Cuppen E: Next-generation sequencing-based genome diagnostics across clinical genetics centers: implementation choices and their effects. Eur J Hum Genet 23: 1142-1150, 2015.
22. Mardis ER: The impact of next-generation sequencing technology on genetics. Trends Genet 24: 133-141, 2008.
23. Biesecker LG: Hypothesis-generating research and predictive medicine. Genome Res 23: 1051-1053, 2013.
24. Gilissen C, Hoischen A, Brunner HG and Veltman JA: Disease gene identification strategies for exome sequencing. Eur J Hum Genet 20: 490-497, 2012.
25. Lo Iacono M, Monica V, Righi L, Grosso F, Libener R, Vatrano S, Bironzo P, Novello S, Musmeci L, Volante M, Papotti M and Scagliotti GV: Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study. J Thorac Oncol 10: 492-499, 2015.
26. Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, Jarosz M, Curran JA, Balasubramanian S, Bloom T, Brennan KW, Donahue A, Downing SR, Frampton GM, Garcia L, Juhn F, Mitchell KC, White E, White J, Zwirko Z, Peretz T, Nechushtan H, Soussan-Gutman L, Kim J, Sasaki H, Kim HR, Park SI, Ercan D, Sheehan CE, Ross JS, Cronin MT, Jänne PA and Stephens PJ: Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 18: 382-384, 2012.
27. Ladanyi M, Zauderer MG, Krug LM, Ito T, McMillan R, Bott M and Giancotti F: New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment. Clin Cancer Res 18: 4485-4490, 2012.
28. Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, Creaney J, Lake RA, Zakowski MF, Reva B, Sander C, Delsite R, Powell S, Zhou Q, Shen R, Olshen A, Rusch V and Ladanyi M: The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 43: 668-672, 2011.
29. Jensen DE, Proctor M, Marquis ST, Gardner HP, Ha SI, Chodosh LA, Ishov AM, Tommerup N, Vissing H, Sekido Y, Minna J, Borodovsky A, Schultz DC, Wilkinson KD, Maul GG, Barlev N, Berger SL, Prendergast GC and Rauscher FJ 3rd: BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 16: 1097-112, 1998.
30. Yoshikawa Y, Sato A, Tsujimura T, Emi M, Morinaga T, Fukuoka K, Yamada S, Murakami A, Kondo N, Matsumoto S, Okumura Y, Tanaka F, Hasegawa S, Nakano T and Hashimoto-Tamaoki T: Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma. Cancer Sci 103: 868-874, 2012.
31. Lo Iacono M, Monica V, Righi L, Grosso F, Libener R, Vatrano S, Bironzo P, Novello S, Musmeci L, Volante M, Papotti M and Scagliotti GV: Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study. J Thorac Oncol 10: 492-499, 2015.
32. Alakus H, Yost SE, Woo B, French R, Lin GY, Jepsen K, Frazer KA, Lowy AM and Harismendy O: BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma. J Transl Med 13: 122, 2015.
33. Sheffield BS, Tinker AV, Shen Y, Hwang H, Li-Chang HH, Pleasance E, Ch'ng C, Lum A, Lorette J, McConnell YJ, Sun S, Jones SJ, Gown AM, Huntsman DG, Schaeffer DF, Churg A, Yip S, Laskin J and Marra MA: Personalized oncogenomics: clinical experience with malignant peritoneal mesothelioma using whole genome sequencing. PLoS One 10: e0119689, 2015.
34. Musti M, Kettunen E, Dragonieri S, Lindholm P, Cavone D, Serio G and Knuutila S: Cytogenetic and molecular genetic changes in malignant mesothelioma. Cancer Genet Cytogenet 170: 9-15, 2006.
35. Sekido Y: Molecular pathogenesis of malignant mesothelioma. Carcinogenesis 34: 1413-1419, 2013.
36. Illei PB, Rusch VW, Zakowski MF and Ladanyi M: Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res 9: 2108-2113, 2003.
37. Xu J, Kadariya Y, Cheung M, Pei J, Talarchek J, Sementino E, Tan Y, Menges CW, Cai KQ, Litwin S, Peng H, Karar J, Rauscher FJ and Testa JR: Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma. Cancer Res 74: 4388-4397, 2014.
38. Bianchi AB, Mitsunaga SI, Cheng JQ, Klein WM, Jhanwar SC, Seizinger B, Kley N, Klein-Szanto AJ and Testa JR: High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci USA 92: 10854-10858, 1995.
39. Andujar P, Pairon JC, Renier A, Descatha A, Hysi I, Abd-Alsamad I, Billon-Galland MA, Blons H, Clin B, Danel C, Debrosse D, Galateau-Sallé F, Housset B, Laurent-Puig P, Le Pimpec-Barthes F, Letourneux M, Monnet I, Régnard JF, Validire P, Zucman-Rossi J, Jaurand MC and Jean D: Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma. Mutagenesis 28: 323-331, 2013.
40. McMillan R, Zauderer M, Bott M and Ladanyi M: Important recent insights into the genetics and biology of malignant pleural mesothelioma. Ann Cardiothorac Surg 1: 462-465, 2012.
41. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, Ding M, Bamford S, Cole C, Ward S, Kok CY, Jia M, De T, Teague JW, Stratton MR, McDermott U and Campbell PJ: COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res 43: D805-811, 2015.
42. Blomberg C, Nilsson J, Holgersson G, Edlund P, Bergqvist M, Adwall L, Ekman S, Brattström D and Bergström S: Randomized Trials of Systemic Medically-treated Malignant Mesothelioma: A Systematic Review. Anticancer Res 35: 2493-2501, 2015.
43. Stahel RA, Weder W, Lievens Y, Felip E and ESMO Guidelines Working Group: Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5): v126-128, 2010.
44. Garassino MC and Marsoni S: A lesson from vorinostat in pleural mesothelioma. Lancet Oncol 16: 359-360, 2015.
45. Zauderer MG and Krug LM: The evolution of multimodality therapy for malignant pleural mesothelioma. Curr Treat Options Oncol 12: 163-172, 2011.
46. Rusch VW, Rosenzweig K, Venkatraman E, Leon L, Raben A, Harrison L, Bains MS, Downey RJ and Ginsberg RJ: A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 122: 788-795, 2001.
47. Rothschild SI: Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK. Cancers (Basel) 7: 930-949, 2015.
48. Miyanaga A, Masuda M, Tsuta K, Kawasaki K, Nakamura Y, Sakuma T, Asamura H, Gemma A and Yamada T: Hippo pathway gene mutations in malignant mesothelioma: revealed by RNA and targeted exon sequencing. J Thorac Oncol 10: 844-851, 2015.
49. Landreville S1, Agapova OA, Matatall KA, Kneass ZT, Onken MD, Lee RS, Bowcock AM and Harbour JW: Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res 18: 408-416, 2012.
50. Krug LM, Kindler HL, Calvert H, Manegold C, Tsao AS, Fennell D, Öhman R, Plummer R, Eberhardt WE, Fukuoka K, Gaafar RM, Lafitte JJ, Hillerdal G, Chu Q, Buikhuisen WA, Lubiniecki GM, Sun X, Smith M and Baas P: Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol 16: 447-456, 2015.
51. Schulz WL, Tormey CA and Torres R: Computational Approach to Annotating Variants of Unknown Significance in Clinical Next Generation Sequencing. Lab Med 46: 285-289, 2015.
52. Katsanis SH and Katsanis N: Molecular genetic testing and the future of clinical genomics. Nat Rev Genet 14: 415-426, 2013.
53. Souilmi Y, Lancaster AK, Jung J Y, Rizzo E, Hawkins JB, Powles R, Amzazi S, Ghazal H, Tonellato PJ and Wall DP: Scalable and cost-effective NGS genotyping in the cloud. BMC Med Genomics 8: 64, 2015.